Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Cash from Financing Activities (2016 - 2025)

Medifast (MED) has disclosed Cash from Financing Activities for 16 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 200.0% year-over-year to $1000.0, compared with a TTM value of -$564000.0 through Dec 2025, up 62.77%, and an annual FY2025 reading of -$564000.0, up 62.77% over the prior year.
  • Cash from Financing Activities was $1000.0 for Q4 2025 at Medifast, up from -$2000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1000.0 in Q4 2025 and bottomed at -$102.0 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is -$21.4 million, with a median of -$18.2 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities crashed 255.02% in 2022, then soared 200.0% in 2025.
  • Year by year, Cash from Financing Activities stood at -$31.2 million in 2021, then grew by 22.1% to -$24.3 million in 2022, then rose by 26.41% to -$17.9 million in 2023, then surged by 99.99% to -$1000.0 in 2024, then skyrocketed by 200.0% to $1000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for MED at $1000.0 in Q4 2025, -$2000.0 in Q2 2025, and -$563000.0 in Q1 2025.